Clinical Trials Logo

Immune Suppression clinical trials

View clinical trials related to Immune Suppression.

Filter by:

NCT ID: NCT05907135 Completed - Clinical trials for Inflammatory Response

Beet Supplementation, Exercise, Inflammation

Start date: July 15, 2023
Phase: N/A
Study type: Interventional

This study will determine if ingesting a beet-based supplement with nitrates for 2 weeks moderates exercise-induced inflammation.

NCT ID: NCT05793983 Recruiting - Infections Clinical Trials

S100A8/A9 and Innate Immunity in Liver Disease

Start date: September 28, 2021
Phase:
Study type: Observational

This observational study evaluates the concentration of immune protein S100A8/A9 in different liver failure syndromes, its interaction with the immune system and validity as an immunotherapeutic target to improve survival in patients with advanced cirrhosis and/or acute on chronic liver failure.

NCT ID: NCT05739045 Recruiting - Gastric Cancer Clinical Trials

Nivolumab Combined With SOX Used in the Perioperative Treatment

Start date: November 3, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the pathological complete response rate (pCR) of nivolumab combined with SOX (oxaliplatin + S-1) for neoadjuvant therapy of resectable gastric and gastroesophageal junction adenocarcinoma;

NCT ID: NCT05732779 Not yet recruiting - Health Behavior Clinical Trials

Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients

Start date: March 31, 2024
Phase: N/A
Study type: Interventional

We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR) episodes, increased number of hospitalizations, graft failure, and patient mortality. Herein, we propose an innovative approach to promote medication adherence and improve patient and graft outcomes.

NCT ID: NCT05635435 Recruiting - Glioma Clinical Trials

Immune and Inflammatory Indices in Peripheral Blood Predict Prognosis of Glioma and Correlate With Grades and Subtypes

Start date: October 13, 2006
Phase:
Study type: Observational

Our study considered the relevant immune and inflammatory indices, such as immunoglobulin kappa light chain, TNF, and CD4+ Helper T lymphocyte% in a multi-institutional study with a large patient cohort (n=1282) from the east, northeast, and southeast of China. Our study shed light on the association of peripheral immune system status with prognosis, tumor grade, and subtype of glioma, which can potentially benefit future diagnostic and prognostic processes of glioma given its noninvasive nature. Moreover, the preoperative inflammatory status can be leveraged for timely interventions to reverse the immunosuppressive status of cancer patients and enhance anti-tumour immunity of glioma.

NCT ID: NCT05591924 Not yet recruiting - Sepsis Clinical Trials

Early Severe Illness TrAnslational BioLogy InformaticS in Humans

ESTABLISH
Start date: January 11, 2024
Phase:
Study type: Observational [Patient Registry]

Advanced stages of the response to life-threatening infection, severe trauma, or other physiological insults often lead to exhaustion of the homeostatic mechanisms that sustain normal blood pressure and oxygenation. These syndromic presentations often meet the diagnostic criteria of sepsis and/or the acute respiratory distress syndrome (ARDS), the two most common syndromes encountered in the intensive care unit (ICU). Although critical illness syndromes, such as sepsis and ARDS, have separate clinical definitions, they often overlap clinically and share several common injury mechanisms. Moreover, there are no specific therapies for critically ill patients, and as a consequence, approximately 1 in 4 patients admitted to the ICU will not survive. The purpose of this observational study is to identify early patient biologic factors that are present at the time of ICU admission that will help diagnose critical illness syndromes earlier, identify who could benefit most from specific therapies, and enable the discovery of new treatments for syndromes such as sepsis and ARDS.

NCT ID: NCT05409092 Completed - Clinical trials for Inflammatory Response

Astaxanthin, Exercise Inflammation, Skin Health

Start date: January 19, 2022
Phase: N/A
Study type: Interventional

Vigorous exercise can stress the body. Consuming special types of diet supplements may help the body recover better from exercise. This includes a bright red supplement called astaxanthin that is found in certain algae and causes the pink-red color in salmon. Astaxanthin is an antioxidant and may protect cells from damage and improve the way the immune system functions. The main purpose of this study is to determine if 4 weeks of consuming astaxanthin improves recovery from 2.25 hours of intensive running on a treadmill. This study will also measure whether or not astaxanthin supplementation improves skin health

NCT ID: NCT05407701 Completed - Clinical trials for Inflammatory Response

Cranberry Ingestion and Cycling Related Immunity and Inflammation

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

This is a randomized, crossover clinical trial with 25 male and female cyclists. Study participants will ingest polyphenol-rich cranberry juice or placebo juice for 4 weeks under double-blinded procedures, and then crossover to the opposite supplement. The primary objective of this study is to examine the efficacy of 4-weeks ingestion of cranberry juice in moderating exercise-induced inflammation, immune dysfunction, and muscle damage. Outcome measures will include global proteiomics, oxylipins, and cytokines.

NCT ID: NCT05380778 Completed - Clinical trials for Anesthesia Complication

Depth of Anesthesia and Proteomics

Start date: March 1, 2009
Phase: N/A
Study type: Interventional

The primary aim of the study is to compare cellular activity of T-cells, NK-cells and monocytes after anesthesia. Phagocytosis and cellular lysis activity of neutrophils and monocytes are analyzed by flow cytometry. Secondly, we analyze anesthesia induced protein expresssion pattern in the blood. The proteome of monocytes is identified by 3D-gel-chromatography and mass spectrometry (MALDI-TOF).

NCT ID: NCT04885907 Completed - Covid19 Clinical Trials

Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients

Start date: May 25, 2021
Phase: Phase 4
Study type: Interventional

This study will be a randomized, double-blind, placebo-controlled trial of a third dose of Moderna vaccine versus placebo. Participants will be those that have received two doses of mRNA-1273 COVID vaccine (Moderna) at 0 and 1 months. Participants will be randomized 1:1 to receive either a third dose of the mRNA-1273 vaccine or saline placebo at 3 months post initial vaccination.